Ibrutinib | compare suppliers & send inquiries for free
Looking for Ibrutinib 936563-96-1?
Do you want to know more about Ibrutinib? You can find a small explanation about it here. Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and it presents a very promising activity in B cell malignancies. Ibrutinib was developed by Pharmacyclics Inc and in November 2013 was FDA-approved for the treatment of mantle cell lymphoma.
Later, in February 2014, ibrutinib was approved for the treatment of chronic lymphocytic leukemia and it is also indicated for the treatment of patients with Waldenström's Macroglobulinemia. Ibrutinib has also been approved by the EMA for the treatment of chronic lymphocytic leukemia and mantle cell lymphoma. Ibrutinib was approved for use in chronic graft versus host disease in August 2017.
Do you want to buy this product? Send an inquiry to the listed suppliers that meets your quality requirements.
Ibrutinib manufacturers | traders | suppliers
We have 11 companies offering Ibrutinib from 3 different countries.
Get in contact with the supplier of your choice:
- Beijing THTD Pharmaceutical Technology Co., Ltd. from China
- Shandong Octagon Chemicals Limited from China
- Shanghai Bncscitech Co., Ltd from China
- SENOVA Technology Co., Ltd. from China
- Shilpa Medicare from India
- Natco Pharma from India
- Scinopharm from Taiwan
- Wisdom Pharma from China
- Fresenius Kabi Onc. from India
- Chengdu Firster Pharmaceutical Co Ltd from China
- Beijing Lunarsun Pharma from China
Let the supplier know whether you are looking for a product with a specific monograph such as EP (Ph. Eur.), USP, JP, BP or another quality. Or, whether you are looking for hydrochloride (HCl), anhydricum, base, micronisatum or a specific purity.
You can use the filters to find high-quality suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our FAQ page or use the chat box in the corner to get more information about Pharmaoffer.